2. Endocrinology

Endocrinology

Endocrinology

Related Products

PDF 21.44 MB

Found in most species of the animal kingdom, the endocrine system consists of glands that secrete hormones, and receptors that detect and react to the hormones. In response to environmental stimuli, the endocrine system secretes hormones and uses them as chemical messengers to orchestrate physiological, developmental and reproductive changes that affect the entire body for a long period of time. In order to maintain the proper functioning of the body through its entire life cycle, the endocrine system utilizes a complex feedback mechanism to fine-tune the balance of hormones in the bloodstream. Even a slight disruption to endocrine system’s function can throw off the delicate balance of hormones in the human body and lead to an endocrine disorder, or endocrine disease, such as diabetes, adrenal insufficiency, hyper- or hypothyroidism, and polycystic ovary syndrome (PCOS).

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-15724A
    Vercirnon sodium 886214-18-2 98.04%
    Vercirnon (GSK1605786A) sodium is an orally bioavailable, selective, and potent antagonist of CCR9. Vercirnon sodium inhibits CCR9-mediated Ca2+ mobilization and chemotaxis on Molt-4 cells with IC50 values of 5.4 and 3.4 nM, respectively. Vercirnon sodium is selective for CCR9 over CCR1-12 and CX3CR1-7 (IC50s>10 μM for all). Vercirnon sodium is an equipotent inhibitor of CCL25-directed chemotaxis of both splice forms of CCR9 (CCR9A and CCR9B) with IC50 values of 2.8 and 2.6 nM, respectively.
    Vercirnon sodium
  • HY-116392B
    DL-threo-PDMP hydrochloride 80938-69-8 99.40%
    DL-threo-PDMP hydrochloride is a competitive glucosylceramide synthase (GCS) inhibitor and antimalarial agent. DL-threo-PDMP hydrochloride competitively inhibits the activity of GCS. DL-threo-PDMP hydrochloride restores cisplatin sensitivity in cisplatin-resistant testicular germ cell tumor cells. DL-threo-PDMP hydrochloride blocks the growth of ring-stage Plasmodium falciparum parasites.
    DL-threo-PDMP hydrochloride
  • HY-13948F1
    Angiotensin II human, FAM-labeled 99.58%
    Angiotensin II human, FAM-labeled (Angiotensin II, FAM-labeled) is a FAM labeled Angiotensin II human (HY-13948).
    Angiotensin II human, FAM-labeled
  • HY-W011240
    Hydroflumethiazide 135-09-1 99.4%
    Hydroflumethiazide (Methforylthiazidine) is an orally active and potent thiazide diuretic. Hydroflumethiazide possesses the ability to directly stimulate A cell secretion in the normal and alloxan diabetic pancreas.
    Hydroflumethiazide
  • HY-16978
    TG6-10-1 1415716-58-3 99.50%
    TG6-10-1 is an EP2 antagonist, shows low-nanomolar antagonist activity against only EP2, >300-fold selectivity over human EP3, EP4, and IP receptors, 100-fold selectivity over EP1 receptors.
    TG6-10-1
  • HY-121528
    Nilestriol 39791-20-3 98.93%
    Nilestriol is a estriol derivative, which inhibits osteoporosis on ovariectomized rats or postmenopausal women.
    Nilestriol
  • HY-A0070R
    Liothyronine sodium (Standard) 55-06-1 98.70%
    Liothyronine (sodium) (Standard) is the analytical standard of Liothyronine (sodium). This product is intended for research and analytical applications. Liothyronine sodium is an active form of thyroid hormone. Liothyronine sodium is a potent thyroid hormone receptors TRα and TRβ agonist with Kis of 2.33 nM for hTRα and hTRβ, respectively.
    Liothyronine sodium (Standard)
  • HY-14432
    Pavinetant 941690-55-7 99.63%
    Pavinetant (MLE-4901) is a neurokinin-3 receptor (NK3R) antagonist.
    Pavinetant
  • HY-14778
    Retosiban 820957-38-8 98.95%
    Retosiban (GSK221149A) is a potent, selective, and orally active oxytocin receptor antagonist (Ki (hOT) = 0.65 nM, Ki (rOT) = 4.1 nM) with no detectable agonist activity. Retosiban has nanomolar affinity for the oxytocin receptor with >1400-fold selectivity over the closely related vasopressin receptors. Retosiban inhibits spontaneous and induces uterine contractions. Retosiban can be studied in research for preterm labour.
    Retosiban
  • HY-14850
    Sograzepide 155488-25-8 98.04%
    Sograzepide (Netazepide; YF 476; YM-220) is an extremely potent, highly selective and orally active Gastrin/CCK-B antagonist with an IC50 value of 0.1 nM, has inhibitory effect on Gastrin/CCK-A activity with an IC50 of 502 nM. Sograzepide (Netazepide; YF 476; YM-220) replaces the specific binding of [125I]CCK-8 to the rat brain, cloned canine and cloned human Gastrin/CCK-B receptors, with Ki values of 0.068, 0.62 and 0.19 nM, respectively.
    Sograzepide
  • HY-B0371
    Terazosin 63590-64-7 99.28%
    Terazosin is a quinazoline derivative and a competitive and orally active α1-adrenoceptor antagonist. Terazosin works by relaxing blood vessels and the opening of the bladder. Terazosin has the potential for benign prostatic hyperplasia (BPH) and high blood pressure treatment.
    Terazosin
  • HY-P0051
    Lecirelin 61012-19-9 99.61%
    Lecirelin, a synthetic gonadotropin-releasing hormone (GnRH) analogue, acts as a GnRH agonist. Lecirelin is widely used for the research of bovine ovarian follicular cysts.
    Lecirelin
  • HY-100186
    GSK-2881078 1539314-06-1 99.42%
    GSK-2881078 is an orally active and nonsteroidal selective androgen receptor modulator (SARM) which act as partial AR agonists in androgenic tissues while mainly as complete AR agonists in synthetic metabolic tissues,induces AR-mediated transcriptional activation in PC3(AR)2 cells (EC50 = 3.99 nM) and the effect can be inhibited by the non-steroidal AR antagonist Bicalutamide. GSK-2881078 can be used in research of muscle weakness and cachexia associated with both chronic and acute illness.
    GSK-2881078
  • HY-109024
    Balovaptan 1228088-30-9 99.89%
    Balovaptan (RG7314) is an orally available, selective brain-penetrant vasopressin 1a (hV1a) receptor antagonist, with Kis of 1 and 39 nM for human (hV1a) and mouse (mV1a) receptors, and is used for the research of autism.
    Balovaptan
  • HY-16465A
    IRL-1620 TFA 98.73%
    IRL-1620 (TFA) is a potent and selective endothelin receptor type B (ETB) agonist with a Ki of 16 pM.
    IRL-1620 TFA
  • HY-17498S
    Atenolol-d7 1202864-50-3 99.62%
    Atenolol-d7 is the deuterium labeled Atenolol. Atenolol ((RS)-Atenolol) is a cardioselective β1-adrenergic receptor blocker, with a Ki of 697 nM atβ1-adrenoceptor in guine pig left ventricle membrane. Atenolol can be used for the research of hypertension and angina pectoris.
    Atenolol-d7
  • HY-10561
    RU 58841 154992-24-2 99.72%
    RU 58841 (PSK-3841) is a specific androgen receptor antagonist or anti-androgen. RU 58841 has a dramatic effect on hair regrowth.
    RU 58841
  • HY-12397
    ZK159222 156965-15-0 99.23%
    ZK159222, a 25-carboxylic ester analogue of 1α,25-(OH)2D3, is a potent 1α,25-(OH)2D3 receptor (VDR) antagonist. The mechanism of ZK159222 antagonistic action is mediated by a lack of ligand-induced vitamin D receptor interaction with coactivators. ZK159222 has a partial agonistic character.
    ZK159222
  • HY-12760
    Indoramin 26844-12-2 99.03%
    Indoramin is an orally active antihypertensive agent. Indoramin is also selective for the α1A-adrenoceptor.
    Indoramin
  • HY-14875
    Verucerfont 885220-61-1 99.93%
    Verucerfont is a corticotropin-releasing factor receptor 1 (CRF1) antagonist with IC50s of ~6.1, >1000 and >1000?nM for CRF1, CRF2, and CRF-BP, respectively.
    Verucerfont
Cat. No. Product Name / Synonyms Application Reactivity